We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 12, 2020

Gemcitabine/Nab-Paclitaxel Until Progression or Alternating With FOLFIRI.3 for Metastatic Pancreatic Adenocarcinoma

European Journal of Cancer


Additional Info

European Journal of Cancer
Gemcitabine Plus Nab-Paclitaxel Until Progression or Alternating With FOLFIRI.3, as First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 Randomised Phase II Study (FIRGEMAX)
Eur. J. Cancer 2020 Jul 02;136(xx)25-34, Y Rinaldi, AL Pointet, F Khemissa Akouz, K Le Malicot, B Wahiba, S Louafi, A Gratet, L Miglianico, H Laharie, K Bouhier Leporrier, A Thirot Bidault, P Texereau, R Coriat, E Terrebonne, MC Gouttebel, D Malka, JB Bachet, C Lepage, J Taieb

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading